Abstract
BackgroundChimeric antigen receptor (CAR) T-cells have shown remarkable success in the treatment of hematological malignancies, but many patients still relapse. One common adverse on-target effect of CAR T-cells is cytokine...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have